Search Results

You are looking at 161 - 170 of 2,748 items for :

  • Refine by Access: All x
Clear All
Full access

Treatment Patterns and Outcomes in Patients With Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories

Kuan-Ling Kuo, David Stenehjem, Frederick Albright, Saurabh Ray, and Diana Brixner

, 31% (n=68) of patients received no treatment ( Table 3 ). From 1995 to 1998, most patients did not receive any treatment. Liver-directed therapy became more prevalent from 2007 to 2010 ( Figure 2 ). Survival Outcomes No statistically

Full access

Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review

Andrew J. Portuguese, Scott S. Tykodi, Christopher D. Blosser, Ted A. Gooley, John A. Thompson, and Evan T. Hall

are now eligible for treatment with ICIs. 8 Due to the need for chronic immunosuppressive therapy, SOTRs with cancer have been consistently excluded from clinical trials with ICIs. 9 – 16 Thus, clinical outcomes for cancers arising in SOTRs treated

Full access

Impact of Provider Imaging Practices on Survival Outcomes in Advanced Ovarian Cancer

Angela K. Green, Deborah Korenstein, Carol Aghajanian, Brooke Barrow, Michael Curry, and Roisin E. O’Cearbhaill

supporting evidence that it improves outcomes. 1 , 2 Yet imaging, either in response to patient symptoms or for surveillance, is common in the management of patients with ovarian cancer in first remission among providers at academic medical centers. 3 In a

Full access

First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort

Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group

RCTs. It should be mentioned that PS was not found in 25% of patients. Therefore, real-world data are a valuable addition to trial results because they deepen the understanding of the outcome of therapies in patients encountered on a day-to-day basis

Full access

Multiple Approvals, Celestial Prices, Unimproved Outcomes: The Tale of Cost-Ineffective Drugs in Hepatocellular Carcinoma

Bishal Gyawali

or none a decade ago, but the billion dollar question is whether outcomes for patients with advanced liver cancer have improved as a result. Some of the statistics are concerning. Although it is too early to observe the effect of new drug approvals

Full access

Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors

Mohammad Abu Zaid, Wambui G. Gathirua-Mwangi, Chunkit Fung, Patrick O. Monahan, Omar El-Charif, Annalynn M. Williams, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra K. Althouse, Shirin Ardeshir-Rouhani-Fard, Paul C. Dinh Jr, Howard D. Sesso, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis, and for the Platinum Study Group

: TCS completed a questionnaire regarding health outcomes, lifestyle behaviors, and current prescription medications (including antihypertensive, diabetic, and lipid-lowering medications). Demographic information included age at cancer diagnosis and

Full access

Joining Together to Improve Outcomes: Integrating Specialty Palliative Care Into the Care of Patients With Cancer

Maxwell T. Vergo and Amelia M. Cullinan

process, and therefore involvement at least 3 to 6 months before cessation of chemotherapy would be ideal to affect outcomes. Figure 1. Palliative care integrated into the continuum of care. Applying these criteria to the present case, Mr

Full access

Enrollment Criteria Controversies for Active Surveillance and Triggers for Conversion to Treatment in Prostate Cancer

David D. Buethe and Julio Pow-Sang

remains to optimize the criteria that qualify a man as either low risk or very low risk, and to establish standardized criteria defining disease progression. Further, there is a paucity of reports on the long-term outcomes of men electing to delay or forgo

Full access

HSR23-095: Outcomes of Patients With Pancreatic Cancer Undergoing Duodenal Stent Placement: A Population-Based Study

Neethi Dasu, Kirti Dasu, Jason John, Yaser Khalid, Lucy Joo, Brian Blair, and C. Jonathan Foster

, duodenal stents are used to treat patients who are considered high-risk surgical candidates. We aimed to study the survival and clinical outcomes after endoscopic duodenal stent placement for patients with pancreatic cancer in comparison to patients who do

Full access

Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance

P. Travis Courtney, Rishi Deka, Nikhil V. Kotha, Daniel R. Cherry, Mia A. Salans, Tyler J. Nelson, Abhishek Kumar, Elaine Luterstein, Anthony T. Yip, Vinit Nalawade, J. Kellogg Parsons, A. Karim Kader, Tyler F. Stewart, and Brent S. Rose

studies of AS in intermediate-risk disease have been limited by small sample sizes, short follow-up, and lack of definitive clinical outcomes, including metastasis and prostate cancer–specific mortality (PCSM). 5 – 12 Nevertheless, the use of AS in